Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Operating Cash Flow
Cash generated by the company's core business operations during the period.
Harrow Health, Inc.NASDAQ: HROW
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns negative
Q1 FY2026 operating cash flow was -$8.99M, compared with $19.67M a year earlier. Trailing-twelve-month operating cash flow was $15.2M. Over 3 fiscal years it compounded at +195.2% a year.
Context
- Operating cash flow amounted to 16.1% of revenue in FY2025, up 5.0 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near -$8.99M or moves back toward the trailing-twelve-month quarterly average of $3.8M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 43.86M USD
- Year-over-year change
- +297.6%
- 4-year CAGR
- +71.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.86M | +297.6% |
| FY2024 | 2024-12-31 | (22.2M) | -678.2% |
| FY2023 | 2023-12-31 | 3.84M | +125.2% |
| FY2022 | 2022-12-31 | 1.71M | -66.5% |
| FY2021 | 2021-12-31 | 5.08M | — |
Operating Cash Flow vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +626.1% is the highest of 8, against a peer median of +55.5%.
- Operating cash flow amounts to 5.7% of revenue for HROW, versus a peer median of 1974.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $458.39M USD | +146.4% | -6.4% | 8.6% | |
| LTM Mar 2026 | $267.54M USD | +80.6% | +54.6% | 3513.3% | |
| LTM Mar 2026 | $226.21M USD | +55.5% | +50.9% | 434.7% | |
| LTM Sep 2026 | $169.49M USD | +33.8% | -13.0% | — | |
| LTM Mar 2026 | CHF 62.18M CHF | +16.7% | +35.4% | 12337.0% | |
| LTM Sep 2026 | $49.9M USD | +192.5% | -36.7% | 7.3% | |
| LTM Mar 2026 | $47.05M USD | -26.5% | -2.9% | 14121.8% | |
| LTM Mar 2026 | $15.2M USD | +626.1% | +195.2% | 5.7% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.9M USD | — | — | — |
| Peer median (excluding HROW) | — | +55.5% | -2.9% | 1974.0% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Depreciation & Amortization | 2.4M | 3.67M | 12.34M | 14.54M | 19.68M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.75M | 7.97M | 15.7M | 17.62M | 12.5M |
| Change in Working Capital | (253K) | (5.57M) | (7.14M) | (44.63M) | 185K |
| Accounts Receivables | (1.83M) | (1.86M) | (30.34M) | (80.23M) | 5.01M |
| Inventory | (255K) | (2.32M) | (4.33M) | 165K | (2.82M) |
| Accounts Payables | 1.73M | 933K | 31.8M | 37.5M | (4.61M) |
| Other Working Capital | 103K | (2.32M) | (4.26M) | (2.06M) | 2.6M |
| Other Non-Cash Items | 15.2M | 9.72M | 7.35M | 7.75M | 16.64M |
| Operating Cash Flow | 5.08M | 1.71M | 3.84M | (22.2M) | 43.86M |
| Capital Expenditures | (28.51M) | (7.77M) | (152.55M) | (38.67M) | (1.1M) |
| Acquisitions (Net) | 9.83M | 0 | 0 | 0 | (4.36M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 9.83M | 0 | 0 | 5.51M | 0 |
| Other Investing Activities | (36.55M) | 854K | (151.09M) | (37.08M) | (215K) |
| Investing Cash Flow | (18.69M) | (1.74M) | (152.55M) | (33.16M) | (5.46M) |
| Debt Repayment | 71.07M | 31.72M | 74.64M | 29.78M | 11.84M |
| Common Stock Issued | 0 | 22.66M | 64.52M | 0 | 467K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (127K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | (234K) | (12.63M) | (1.25M) | (25.04M) |
| Financing Cash Flow | 51.47M | 54.14M | 126.53M | 28.53M | (12.72M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.87M | 54.1M | (22.19M) | (26.84M) | 25.68M |
| Free Cash Flow | (23.43M) | (6.07M) | (148.71M) | (60.88M) | 42.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.